2019 Q3 Form 10-Q Financial Statement

#000156459019038842 Filed on October 30, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $22.85M $19.33M $15.42M
YoY Change 18.21% 79.03% 61.89%
Cost Of Revenue $7.580M $8.140M $7.720M
YoY Change -6.88% 52.15% 77.06%
Gross Profit $15.26M $11.19M $7.700M
YoY Change 36.37% 105.36% 49.08%
Gross Profit Margin 66.78% 57.89% 49.94%
Selling, General & Admin $16.14M $13.96M $14.44M
YoY Change 15.62% 14.61% 2.46%
% of Gross Profit 105.77% 124.75% 187.49%
Research & Development $16.08M $10.83M $9.881M
YoY Change 48.48% 37.33% 11.15%
% of Gross Profit 105.37% 96.78% 128.32%
Depreciation & Amortization -$130.0K $320.0K $380.0K
YoY Change -140.62% -30.43% -11.63%
% of Gross Profit -0.85% 2.86% 4.94%
Operating Expenses $32.22M $24.79M $24.32M
YoY Change 29.97% 23.24% 5.57%
Operating Profit -$16.96M -$13.60M -$12.57M
YoY Change 24.71% 9.84% -22.42%
Interest Expense -$1.290M -$1.050M $958.0K
YoY Change 22.86% -196.33% 91.22%
% of Operating Profit
Other Income/Expense, Net $340.0K $510.0K -$652.0K
YoY Change -33.33% -151.72% -121.76%
Pretax Income -$17.91M -$14.14M -$13.22M
YoY Change 26.66% 5.77% 0.12%
Income Tax $60.00K $60.00K $59.00K
% Of Pretax Income
Net Earnings -$17.97M -$14.19M -$13.28M
YoY Change 26.6% 5.77% -22.25%
Net Earnings / Revenue -78.63% -73.42% -86.13%
Basic Earnings Per Share -$0.13 -$0.11 -$0.10
Diluted Earnings Per Share -$0.13 -$0.11 -$0.10
COMMON SHARES
Basic Shares Outstanding 131.4M
Diluted Shares Outstanding 131.4M

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.10M $119.0M $111.9M
YoY Change -28.48% 99.66% 119.84%
Cash & Equivalents $27.10M $22.33M $17.03M
Short-Term Investments $60.70M $96.67M $97.60M
Other Short-Term Assets $5.800M $7.400M $4.970M
YoY Change -21.62% 80.49% 50.61%
Inventory $20.91M $13.30M $12.93M
Prepaid Expenses
Receivables $14.50M $10.50M $11.39M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $126.3M $150.2M $141.2M
YoY Change -15.91% 69.91% 90.04%
LONG-TERM ASSETS
Property, Plant & Equipment $29.30M $3.100M $2.157M
YoY Change 845.16% 34.78% -20.11%
Goodwill $1.316M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.300M $6.700M $4.011M
YoY Change 8.96% 52.27% -12.8%
Total Long-Term Assets $38.10M $11.50M $10.65M
YoY Change 231.3% 32.18% 15.74%
TOTAL ASSETS
Total Short-Term Assets $126.3M $150.2M $141.2M
Total Long-Term Assets $38.10M $11.50M $10.65M
Total Assets $164.4M $161.7M $151.8M
YoY Change 1.67% 66.53% 81.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.00M $13.00M $11.31M
YoY Change 53.85% 4.0% 17.78%
Accrued Expenses $18.45M $18.10M $12.51M
YoY Change 1.93% 69.16% 34.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $5.700M $3.600M
YoY Change -12.28% -34.55%
Total Short-Term Liabilities $45.60M $43.20M $28.06M
YoY Change 5.56% 80.75% 10.92%
LONG-TERM LIABILITIES
Long-Term Debt $39.40M $24.10M $26.30M
YoY Change 63.49% -19.13% 121.01%
Other Long-Term Liabilities $18.70M $2.500M $1.329M
YoY Change 648.0% -60.32% -81.01%
Total Long-Term Liabilities $58.10M $26.60M $1.329M
YoY Change 118.42% -26.32% -92.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.60M $43.20M $28.06M
Total Long-Term Liabilities $58.10M $26.60M $1.329M
Total Liabilities $103.6M $69.90M $61.40M
YoY Change 48.21% 16.69% 38.92%
SHAREHOLDERS EQUITY
Retained Earnings -$748.5M
YoY Change
Common Stock $839.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.81M $91.80M $90.44M
YoY Change
Total Liabilities & Shareholders Equity $164.4M $161.7M $151.8M
YoY Change 1.67% 66.55% 81.85%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$17.97M -$14.19M -$13.28M
YoY Change 26.6% 5.77% -22.25%
Depreciation, Depletion And Amortization -$130.0K $320.0K $380.0K
YoY Change -140.62% -30.43% -11.63%
Cash From Operating Activities -$22.22M -$4.890M -$8.930M
YoY Change 354.4% -61.95% -31.31%
INVESTING ACTIVITIES
Capital Expenditures -$1.940M -$470.0K -$100.0K
YoY Change 312.77% -37.5%
Acquisitions
YoY Change
Other Investing Activities $11.97M $1.010M -$6.770M
YoY Change 1085.15% -108.18% -157.08%
Cash From Investing Activities $10.02M $530.0K -$6.870M
YoY Change 1790.57% -104.3% -158.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.06M 12.39M 15.13M
YoY Change 5.41% -43.42% 42.07%
NET CHANGE
Cash From Operating Activities -22.22M -4.890M -8.930M
Cash From Investing Activities 10.02M 530.0K -6.870M
Cash From Financing Activities 13.06M 12.39M 15.13M
Net Change In Cash 860.0K 8.030M -670.0K
YoY Change -89.29% -344.82% -107.18%
FREE CASH FLOW
Cash From Operating Activities -$22.22M -$4.890M -$8.930M
Capital Expenditures -$1.940M -$470.0K -$100.0K
Free Cash Flow -$20.28M -$4.420M -$8.830M
YoY Change 358.82% -65.6% -31.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue Practical Expedient Remaining Performance Obligation
RevenuePracticalExpedientRemainingPerformanceObligation
true
cers Product Warranty Term
ProductWarrantyTerm
P1Y
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-17967000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
73000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24151000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
624000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
80453000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
30002000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51075000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7150000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25056000
CY2019Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2900000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5750000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7459000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1876000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3005000
cers Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
-1377000
CY2019Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2018Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13930000
CY2019Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2018Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
500000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
161000
CY2019Q1 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
684000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
211000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-18792000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
69500000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9836000
CY2019Q2 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsValue
558000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-17562000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
65632000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7914000
CY2019Q3 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
1586000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3595000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
48000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
60808000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57262000
CY2018Q1 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
1295000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2315000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-329000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13885000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
85598000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11910000
CY2018Q2 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsValue
3616000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13282000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
90444000
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10319000
CY2018Q3 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
2468000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2671000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
91000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14192000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
91801000
us-gaap Profit Loss
ProfitLoss
-54321000
us-gaap Profit Loss
ProfitLoss
-41359000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1781000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1109000
us-gaap Share Based Compensation
ShareBasedCompensation
9612000
us-gaap Share Based Compensation
ShareBasedCompensation
7579000
cers Non Cash Lease Expense
NonCashLeaseExpense
1224000
cers Non Cash Interest Expense
NonCashInterestExpense
343000
cers Non Cash Interest Expense
NonCashInterestExpense
892000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-14000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1939000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1043000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2724000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3020000
cers Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
4459000
cers Increase Decrease In Manufacturing And Development Payment Liability
IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
-6288000
cers Increase Decrease In Manufacturing And Development Payment Liability
IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
-187000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
63000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57277000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8460000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17803000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
79301000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
4993000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
39433000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
31080000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
99000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34003000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86352000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4490000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11126000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31587000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27097000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
34756000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
62000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18784000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2854000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (“SSP”) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p>
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At September 30, 2019, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents and short-term investments.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its unaudited condensed consolidated balance sheets and records a charge on its unaudited condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had two customers that each accounted for more than 10% of the Company’s outstanding trade receivables at September 30, 2019 and December 31, 2018. These customers cumulatively represented approximately 47% and 50% of the Company’s outstanding trade receivables at September 30, 2019 and December 31, 2018, respectively. To date, the Company has not experienced collection difficulties from these customers.</p>
CY2018Q4 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
2
CY2019Q3 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
2
cers Work In Process Inventory Life Period
WorkInProcessInventoryLifePeriod
P1Y
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
300000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
900000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1800000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1700000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2018Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21492000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19874000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at September 30, 2019 and December 31, 2018.</p>
CY2019Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2018Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
71179000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94885000
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5453000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3075000
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15453000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10464000
CY2019Q3 us-gaap Inventory Net
InventoryNet
20906000
CY2018Q4 us-gaap Inventory Net
InventoryNet
13539000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9082000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10765000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4337000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4544000
CY2019Q3 cers Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
1804000
CY2018Q4 cers Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
1965000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3226000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2526000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18449000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19800000
cers Minimum Term Of Non Cancelable Operating Leases
MinimumTermOfNonCancelableOperatingLeases
P1Y
cers Expiration Of Non Cancelable Operating Leases Maximum Year
ExpirationOfNonCancelableOperatingLeasesMaximumYear
2030
us-gaap Operating Lease Payments
OperatingLeasePayments
2372000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12974000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M6D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
854000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3114000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3139000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2768000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2644000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
18701000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31220000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11170000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
20050000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
800000
CY2018Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
2300000
us-gaap Operating Lease Cost
OperatingLeaseCost
1000000.0
us-gaap Lessor Operating Lease Lease Not Yet Commenced Description
LessorOperatingLeaseLeaseNotYetCommencedDescription
the Company had no leases that have not yet commenced.
CY2019Q3 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
9800000
CY2018Q3 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
5600000
cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
23300000
cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
15700000
CY2019Q3 cers Accrual For Manufacturing Of Entity Products
AccrualForManufacturingOfEntityProducts
8223000
CY2018Q4 cers Accrual For Manufacturing Of Entity Products
AccrualForManufacturingOfEntityProducts
7812000
CY2019Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
1325000
CY2018Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
1777000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1

Files In Submission

Name View Source Status
0001564590-19-038842-index-headers.html Edgar Link pending
0001564590-19-038842-index.html Edgar Link pending
0001564590-19-038842.txt Edgar Link pending
0001564590-19-038842-xbrl.zip Edgar Link pending
cers-10q_20190930.htm Edgar Link pending
cers-10q_20190930_htm.xml Edgar Link completed
cers-20190930.xsd Edgar Link pending
cers-20190930_cal.xml Edgar Link unprocessable
cers-20190930_def.xml Edgar Link unprocessable
cers-20190930_lab.xml Edgar Link unprocessable
cers-20190930_pre.xml Edgar Link unprocessable
cers-ex311_8.htm Edgar Link pending
cers-ex312_6.htm Edgar Link pending
cers-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending